180 related articles for article (PubMed ID: 24980822)
21. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.
Yegin Z; Gunes S; Buyukalpelli R
DNA Cell Biol; 2013 Jul; 32(7):386-92. PubMed ID: 23682613
[TBL] [Abstract][Full Text] [Related]
22. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas.
Pina-Cabral L; Santos L; Mesquita B; Amaro T; Magalhães S; Criado B
Clin Transl Oncol; 2007 Nov; 9(11):731-6. PubMed ID: 18055328
[TBL] [Abstract][Full Text] [Related]
23. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
24. Correlation of CCNA1 promoter methylation with malignant tumors: a meta-analysis introduction.
Yang B; Miao S; Zhang LN; Sun HB; Xu ZN; Han CS
Biomed Res Int; 2015; 2015():134027. PubMed ID: 25654082
[TBL] [Abstract][Full Text] [Related]
25. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
27. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.
Shindo T; Shimizu T; Nojima M; Niinuma T; Maruyama R; Kitajima H; Kai M; Itoh N; Suzuki H; Masumori N
Urology; 2018 Mar; 113():71-78. PubMed ID: 29196070
[TBL] [Abstract][Full Text] [Related]
29. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
Chen X; Liu L; Mims J; Punska EC; Williams KE; Zhao W; Arcaro KF; Tsang AW; Zhou X; Furdui CM
Epigenetics; 2015; 10(6):545-61. PubMed ID: 25961636
[TBL] [Abstract][Full Text] [Related]
30. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
31. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer.
Eissa S; Zohny SF; Shehata HH; Hegazy MG; Salem AM; Esmat M
Clin Biochem; 2012 Apr; 45(6):402-7. PubMed ID: 22286019
[TBL] [Abstract][Full Text] [Related]
32. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence.
Li H; Wang J; Xiao W; Xia D; Lang B; Wang T; Guo X; Hu Z; Ye Z; Xu H
J Urol; 2014 Feb; 191(2):493-501. PubMed ID: 24018236
[TBL] [Abstract][Full Text] [Related]
34. Methylation profiling of urothelial carcinoma in bladder biopsy and urine.
Pu RT; Laitala LE; Clark DP
Acta Cytol; 2006; 50(5):499-506. PubMed ID: 17017434
[TBL] [Abstract][Full Text] [Related]
35. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
[TBL] [Abstract][Full Text] [Related]
38. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
39. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
[TBL] [Abstract][Full Text] [Related]
40. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
